Fmr Llc - Dec 22, 2023 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role
Other*, 10%+ Owner
Signature
Bryan Comtois, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
GPCR
Transactions as of
Dec 22, 2023
Transactions value $
$0
Form type
4
Date filed
12/27/2023, 10:49 AM
Previous filing
Dec 7, 2023
Next filing
Jan 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GPCR Ordinary Shares 45.1K Dec 22, 2023 F-Prime Capital Partners Life Sciences Advisors Fund VI LP
holding GPCR Ordinary Shares 531K Dec 22, 2023 F-Prime Capital Partners Life Sciences Fund VI LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GPCR American Depositary Shares Other $0 -25.4K -1.6% $0.00 1.56M Dec 22, 2023 Ordinary Shares 76.2K Shares held by persons and entities whose shares are subject to reporting by the undersigned F1, F2
holding GPCR American Depositary Shares 41 Dec 22, 2023 Ordinary Shares 123 FIMM, LLC F1
holding GPCR American Depositary Shares 2.73K Dec 22, 2023 Ordinary Shares 8.2K F-Prime Capital Partners Life Sciences Advisors Fund VI LP F1
holding GPCR American Depositary Shares 32.2K Dec 22, 2023 Ordinary Shares 96.5K F-Prime Capital Partners Life Sciences Fund VI LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.
F2 These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC.